Electric Car Stock News: Car Charging Group (OTCBB:CCGI) Awarded $1 Million Grant by Pennsylvania Department of EP
MIAMI BEACH, Fla. - December 15, 2011 (Investorideas.com Renewable Energy Newswire) - Car Charging Group, Inc. (OTCBB:CCGI.OB), a provider of electric vehicle (EV) charging services, today announced it has been awarded a $1 million grant by the Pennsylvania Department of Environmental Protection to install EV charging stations at 17 service plazas on the Pennsylvania Turnpike.
"This grant represents a tremendous accomplishment for our Company and endorsement of our industry leading capabilities to install and operate EV charging stations," said Michael D. Farkas, CEO of Car Charging Group. "We are extremely excited about this major project with the Pennsylvania Department of Environmental Protection to further develop EV infrastructure on the Pennsylvania Turnpike."
"Pennsylvania has been -- and will continue to be -- a nationwide leader on energy issues in all sectors," Pennsylvania Department of Environmental Protection Secretary Mike Krancer said.
"The Pennsylvania Turnpike has a long history of innovation in highway transportation," Turnpike Commission Chairman William K. Lieberman said. "We are pleased to participate in the effort to expand the electric vehicle charging infrastructure in Pennsylvania by offering electric car owners easy access to charging stations at convenient locations."
Car Charging Group will install Level II charging stations, which can charge a car in roughly four hours, and Level III charging stations, which can charge a car in about 20 minutes. The EV charging stations will be installed at the service plazas in three phases. The first phase of the work will be incorporated into ongoing service-plaza renovations between Harrisburg and New Jersey. Later phases will involve service plazas between Harrisburg and Ohio, and then along the Northeastern Extension. The project is expected to be completed by June 30, 2013.
Car Charging Group will install EV charging stations manufactured by Coulomb Technologies, the leading EV charging solutions company. Users will have access to the ChargePoint(R) Network, the largest global online network connecting EV drivers to unoccupied charging stations. Car Charging Group will provide flexible payment options, the ability to make reservations, and tracking of customer usage patterns, energy use, costs and revenues, all via the ChargePoint Network's cloud-based software service plans for managing EV charging operations. Through the network, EV drivers benefit from ChargePoint mobile apps (iPhone, Blackberry and Android), mapping services and driver support services.
The Turnpike Commission has also committed up to $500,000 in electric upgrades at the plazas to provide the charging stations with the necessary voltage.
The DEP grant is provided through the Alternative Fuels Incentive Grant Program, which is funded by a portion of the gross utilities receipts tax.
About Car Charging Group, Inc.:
Car Charging Group, Inc. (OTCBB:CCGI.OB), headquartered in Miami, Florida, is the pioneer and one of the nation's fastest growing providers of EV charging services. Our ultimate mission is to establish a nationwide infrastructure, enabling EV and Plug-in Hybrid Electric Vehicle (PHEV) owners to charge their EVs anytime, anywhere in North America and ultimately Europe and Asia. Our strategy is to be a "first in" strategic partner with businesses, municipalities, shopping malls, parking garages, multi-family residential and commercial properties, and others who are expected to have high numbers of EVs at their locations. After strategically assessing the most suitable and visible locations with our facility partners, we install and maintain the EV charging stations at no cost to our partners. Our partners benefit by sharing in the revenue generated from the EV charging stations while enhancing green initiatives throughout their business operations. Since we launched operations in 2009, we have developed contractual relationships with 29 leading partners that own more than 6.4 million parking spots. More than one million plug-in electric vehicles, such as the Nissan LEAF, GM Chevrolet Volt, Fisker Karma, Tesla Model S, Ford Focus EV as well as many others, are expected to be on the road in the U.S. by 2015 with estimates calling for more than 40 million on the road worldwide in 2030. For more information about Car Charging Group, Inc., please visit www.CarCharging.com.
Forward-Looking Safe Harbor Statement:
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees as of 1995. Those statements include statements regarding the intent, belief or current expectations of Car Charging Group, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed.
Contact:
Investor Relations and Media Contact:
For Car Charging Group, Inc.
Kevin S. Inda
Corporate Communications, Inc. (CCI)
kevin.inda@cci-ir.com
407-566-1180
Thursday, December 15, 2011
Biotech/ Pharma Stock Trading Alert: Antares (NYSE Amex: AIS) Trades Down on BioSante News
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced on the close yesterday that its top-line results from its two pivotal Phase III LibiGel (testosterone gel) efficacy trials. Initial analysis of the data from these trials shows that the trials did not meet the co-primary or secondary endpoints. Although there were no statistical differences in the endpoints, all results were in the appropriate directions. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in postmenopausal women, for which there is no FDA-approved product. BioSante is trading down at $0.4801, down 1.6399 (77.35%) 12:28PM EST.
Antares' partnership with BioSante includes LibiGel® transdermal testosterone gel in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD).
"Antares Sell-Off is a Holiday Gift"- Josh Levine
"After the market close yesterday, Antares Pharma (AIS) partner Biosante reported results from two Phase III efficacy trials for Libigel, which is used to treat hypoactive sexual desire disorder in post-menopausal women. Here's the bottom line: While Libigel was extremely effective and reinforced previous studies, the placebo group fared nearly as well. The failure appears to have been due to a surprisingly high placebo effect. The impact on Biosante is devastating, but it's only a minor bump in the road for Antares. Today's 30%-plus drop in AIS shares is an overreaction and the stock will rebound fully in time."
He also noted, "Libigel, if successful, would have only begun contributing revenues to Antares in 2015."
About Josh Levine and Levine's MicroCap Investorwww.levinesmicrocapinvestor.com
Josh Levine has 25 years of senior-level experience in analyzing technology trends and investing in top-performing micro- and small-cap stocks.
About Antares Pharma, Inc. (NYSE Amex: AIS)
Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include VIBEX™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors distributed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company's FDA approved product is Anturol® gel, an oxybutynin ATD™ gel for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for the U.S. and Canada. Antares' partnership with BioSante includes LibiGel® transdermal testosterone gel in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin® estradiol gel indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has two facilities in the U.S. The Parenteral Products Division located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company's reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company's corporate offices and Pharma Division are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company's transdermal systems and drug/device combination products.
Get biotech news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure. BPAX compensates investorideas .com for news release dissemination and content creation. BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
What’s Charging the Electric Car Market? – How Car Charging Group (OTCBB: CCGI) and The Better Place are Growing the Global EV Infrastructure
POINT ROBERTS, December 14, 2011 - www.InvestorIdeas.com, a leader in cleantech research and news for independent investors, publishes the following CFA commentary on the EV charging market and how Car Charging Group, Inc. (OTCBB: CCGI) and the Better Place are growing the global infrastructure for electric cars .
The report, Opportunity and Valuation in the Electric Vehicle Charging Market, was issued by Patrick J. Murphy, Murphy Analytics LLC, a provider of sponsored research coverage on small cap stocks.
Opportunity and Valuation in the Electric Vehicle Charging Market
Car Charging Group, Inc. (OTCBB: CCGI), headquartered in Miami, Florida, is one of the nation's fastest growing providers of Electric Vehicle (EV) charging services. The Company’s ultimate mission is to establish a nationwide infrastructure, enabling EV and Plug-in Hybrid Electric Vehicle (PHEV) owners to charge their EVs anytime, anywhere in North America and ultimately Europe and Asia. The CCGI strategy is to be a "first in" strategic partner with businesses, municipalities, shopping malls, parking garages, multi-family residential and commercial properties, and others who are expected to have high numbers of EVs at their locations. Since launching operations in 2009, CCGI has developed contractual relationships with 29 leading partners that own more than 6.4 million parking spots. In addition to working with private enterprise, CCGI also pursues public sector opportunities. As an example, the Pennsylvania Department of Environmental Protection[i] announced 12/14/11 that that CCGI has been awarded a $1 million grant to help develop electric vehicle infrastructure by installing charging stations at 17 Turnpike service plazas.
In an attempt to understand the magnitude of the potential demand load increase, and to prepare for the impact the EV market growth may have on the electric grid, the ISO/RTC Council commissioned a study , “Assessment of Plug-in Electric Vehicle Integration with ISO/RTO Systems,” in which it was estimated that 1 million to 2.5 million EV’s may be on North American roads by 2015 – 2020. The following graphic illustrates the reports conclusion that the “slow” growth scenario is likely to result in 1 million EV by 2020:
For the period from 2017 – 2030, the study finds that: “This period is considered as the beginning of the mass-market...New technologies, advanced features, and new charging capabilities likely will be available. Third-generation PEVs are likely to begin appearing on the market. Most importantly, the vehicles will likely have appeal to mainstream automotive customers and become mass market products.”
With an estimated 842 vehicles per 1,000 citizens in the U.S. alone and the developing world’s per capita vehicle ownership ratios still exponentially below those of the U.S., the potential market opportunity for EV’s and the charging of EV’s is challenging to quantify but not difficult to characterize as very large.
Based on the recent capital raise by EV charging system operator Better Place, it seems clear that investors such as GE, UBS, HSBC and Morgan Stanley have concluded that the opportunity is indeed significant for the right operator. Announced November 11, 2011, Better Place recently completed a $200 million financing that valued the company at $2.25 billion on a post money / fully diluted basis. Better Place also reported that the Company has raised $750 million since its founding in 2007.
The Better Place solution is a model in which batteries are switched out rather than re-charged in the vehicle. According to its corporate description, Better Place “owns and operates a network of battery switch stations and public/personal charge spots, along with the supply of batteries that power the cars, to provide drivers with instant range extension and the convenience to drive, switch and go across an entire region.” Better Place also reported that the financing proceeds would be used to expand operations into Western Europe and that other deployments are in progress in two U.S. states and several other countries.
As a private company, Better Place has no obligation to disclose detailed operational and financial data, so it is challenging to analyze its valuation relative to publicly traded companies such as Car Charging Group (OTCBB: CCGI), which as noted previously, has reported that its partner relationships provide access to 6.4 million parking spots, while CCGI's recent market capitalization was under $65 million.. There are publicly traded companies such as iGo, Inc. (NASDAQ: IGOI) and ZAGG Inc. (NASDAQ: ZAGG) whose operations have some degree of comparability to those of Car Charging Group (OTCBB: CCGI). However, like some of the electronics industry titans with some manner of presence in the sector, Car Charging Group’s (OTCBB: CCGI) comparables generally have operations that also include products and markets other than EV charging systems.
Regardless of the valuation methodology, given the level at which Better Place recently was valued by a group of sophisticated investors, it seems clear that the market is concluding that there is an opportunity to thrive in the car charging sector. Companies with strong systems, management teams, relationships and competitive positions may be worth a closer look for investors interested in finding a way to take advantage of what seems to be a rapidly expanding EV charging market.
Car Charging Group, Inc (OTCBB: CCGI)
Select Stock Trading Data
Recent Stock Price: $1.70
Shares Outstanding: 36.4 million
Float 8.3 million
Recent Market Cap: $62 million
52 Week Range: $0.68 - $6.24
Exchange: OTCBB
Ticker: CCGI
URL: http://www.carcharging.com
Data sourced from Yahoo! Finance; otcbb.com
Patrick Murphy Bio:
Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks. Mr. Murphy has nearly 20 years of capital markets experience providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's. In addition to his work with Murphy Analytics, Mr. Murphy also serves as a consultant to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of the University of Notre Dame (1991), with an undergraduate degree in Economics, and earned a Masters Degree in Finance from St. Louis University in 1997. Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St. Louis.
Patrick Murphy Disclaimer:
Readers are advised that the above article is solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. The views expressed herein are based upon the author’s analysis of the issuer's public disclosures, and assumes both their accuracy and completeness. The opinions and statements included herein are based on sources (including the companies discussed and public sources) believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. The author has not independently verified the information contained herein. This information is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. You should review a complete information package on all companies, which should include, but not be limited to, the Company's annual report, quarterly reports, press releases and all regulatory filings. The foregoing discussion contains statements which are based on current expectations, estimates and projections, and differences from such expectations, estimates and projections can be expected. The author, Patrick Murphy, was compensated $550 by InvestorIdeas.com for writing this article. Murphy does not own shares of any of the companies mentioned in this article. Mr. Murphy’s research firm, Murphy Analytics, may be engaged for the provision of a research report on the Company in the future.
POINT ROBERTS, December 14, 2011 - www.InvestorIdeas.com, a leader in cleantech research and news for independent investors, publishes the following CFA commentary on the EV charging market and how Car Charging Group, Inc. (OTCBB: CCGI) and the Better Place are growing the global infrastructure for electric cars .
The report, Opportunity and Valuation in the Electric Vehicle Charging Market, was issued by Patrick J. Murphy, Murphy Analytics LLC, a provider of sponsored research coverage on small cap stocks.
Opportunity and Valuation in the Electric Vehicle Charging Market
Car Charging Group, Inc. (OTCBB: CCGI), headquartered in Miami, Florida, is one of the nation's fastest growing providers of Electric Vehicle (EV) charging services. The Company’s ultimate mission is to establish a nationwide infrastructure, enabling EV and Plug-in Hybrid Electric Vehicle (PHEV) owners to charge their EVs anytime, anywhere in North America and ultimately Europe and Asia. The CCGI strategy is to be a "first in" strategic partner with businesses, municipalities, shopping malls, parking garages, multi-family residential and commercial properties, and others who are expected to have high numbers of EVs at their locations. Since launching operations in 2009, CCGI has developed contractual relationships with 29 leading partners that own more than 6.4 million parking spots. In addition to working with private enterprise, CCGI also pursues public sector opportunities. As an example, the Pennsylvania Department of Environmental Protection[i] announced 12/14/11 that that CCGI has been awarded a $1 million grant to help develop electric vehicle infrastructure by installing charging stations at 17 Turnpike service plazas.
In an attempt to understand the magnitude of the potential demand load increase, and to prepare for the impact the EV market growth may have on the electric grid, the ISO/RTC Council commissioned a study , “Assessment of Plug-in Electric Vehicle Integration with ISO/RTO Systems,” in which it was estimated that 1 million to 2.5 million EV’s may be on North American roads by 2015 – 2020. The following graphic illustrates the reports conclusion that the “slow” growth scenario is likely to result in 1 million EV by 2020:
For the period from 2017 – 2030, the study finds that: “This period is considered as the beginning of the mass-market...New technologies, advanced features, and new charging capabilities likely will be available. Third-generation PEVs are likely to begin appearing on the market. Most importantly, the vehicles will likely have appeal to mainstream automotive customers and become mass market products.”
With an estimated 842 vehicles per 1,000 citizens in the U.S. alone and the developing world’s per capita vehicle ownership ratios still exponentially below those of the U.S., the potential market opportunity for EV’s and the charging of EV’s is challenging to quantify but not difficult to characterize as very large.
Based on the recent capital raise by EV charging system operator Better Place, it seems clear that investors such as GE, UBS, HSBC and Morgan Stanley have concluded that the opportunity is indeed significant for the right operator. Announced November 11, 2011, Better Place recently completed a $200 million financing that valued the company at $2.25 billion on a post money / fully diluted basis. Better Place also reported that the Company has raised $750 million since its founding in 2007.
The Better Place solution is a model in which batteries are switched out rather than re-charged in the vehicle. According to its corporate description, Better Place “owns and operates a network of battery switch stations and public/personal charge spots, along with the supply of batteries that power the cars, to provide drivers with instant range extension and the convenience to drive, switch and go across an entire region.” Better Place also reported that the financing proceeds would be used to expand operations into Western Europe and that other deployments are in progress in two U.S. states and several other countries.
As a private company, Better Place has no obligation to disclose detailed operational and financial data, so it is challenging to analyze its valuation relative to publicly traded companies such as Car Charging Group (OTCBB: CCGI), which as noted previously, has reported that its partner relationships provide access to 6.4 million parking spots, while CCGI's recent market capitalization was under $65 million.. There are publicly traded companies such as iGo, Inc. (NASDAQ: IGOI) and ZAGG Inc. (NASDAQ: ZAGG) whose operations have some degree of comparability to those of Car Charging Group (OTCBB: CCGI). However, like some of the electronics industry titans with some manner of presence in the sector, Car Charging Group’s (OTCBB: CCGI) comparables generally have operations that also include products and markets other than EV charging systems.
Regardless of the valuation methodology, given the level at which Better Place recently was valued by a group of sophisticated investors, it seems clear that the market is concluding that there is an opportunity to thrive in the car charging sector. Companies with strong systems, management teams, relationships and competitive positions may be worth a closer look for investors interested in finding a way to take advantage of what seems to be a rapidly expanding EV charging market.
Car Charging Group, Inc (OTCBB: CCGI)
Select Stock Trading Data
Recent Stock Price: $1.70
Shares Outstanding: 36.4 million
Float 8.3 million
Recent Market Cap: $62 million
52 Week Range: $0.68 - $6.24
Exchange: OTCBB
Ticker: CCGI
URL: http://www.carcharging.com
Data sourced from Yahoo! Finance; otcbb.com
Patrick Murphy Bio:
Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks. Mr. Murphy has nearly 20 years of capital markets experience providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's. In addition to his work with Murphy Analytics, Mr. Murphy also serves as a consultant to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of the University of Notre Dame (1991), with an undergraduate degree in Economics, and earned a Masters Degree in Finance from St. Louis University in 1997. Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St. Louis.
Patrick Murphy Disclaimer:
Readers are advised that the above article is solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. The views expressed herein are based upon the author’s analysis of the issuer's public disclosures, and assumes both their accuracy and completeness. The opinions and statements included herein are based on sources (including the companies discussed and public sources) believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. The author has not independently verified the information contained herein. This information is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. You should review a complete information package on all companies, which should include, but not be limited to, the Company's annual report, quarterly reports, press releases and all regulatory filings. The foregoing discussion contains statements which are based on current expectations, estimates and projections, and differences from such expectations, estimates and projections can be expected. The author, Patrick Murphy, was compensated $550 by InvestorIdeas.com for writing this article. Murphy does not own shares of any of the companies mentioned in this article. Mr. Murphy’s research firm, Murphy Analytics, may be engaged for the provision of a research report on the Company in the future.
Wednesday's Biotech/ Pharma Stocks Trading; (NASDAQ:AMRI), (NASDAQ:VPHM), (NASDAQ:ZLCS), (NASDAQ:ILMN)
Point Roberts, WA - December 15, 2011 - Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for some of the top trading stocks in the sector for Wednesday, December 14, 2011.
Albany Molecular Research, Inc. (NASDAQ:AMRI) shares gained 0.43 (18.53%) to close at $2.75, rebounding from its recent lows and the stock has surged around 35% over the past 3 weeks.
ViroPharma Incorporated (NASDAQ:VPHM) ended higher by 4.21 (17.85%) to close at $27.80 on very unusual volume and made a new 52-week high of $28.34 after the company reported that U.S. health regulators approved a new and expanded label for its antibiotic Vancocin, which the biotechnology company expects will grant the drug three years of protection from generic versions.
Zalicus, Inc. (NASDAQ:ZLCS) rose 0.10 (9.26%) and closed at $1.18, extending its weekly gains to over 24% on increased volume. Zalicus Inc. (Zalicus), formerly CombinatoRx, is a biopharmaceutical company developing drug candidates with a focus on the treatment of pain and inflammation.
Illumina, Inc. (NASDAQ:ILMN) moved higher by 1.25 (4.82%) to end at $27.21, rebounding from its 52-week low made recently. The stock has a 52-week range of $25.57-$79.40. Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.
Cornerstone Therapeutics, Inc. (NASDAQ:CRTX) climbed 0.52 (10.24%) to finish at $5.60 on high volume. Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, developing and commercializing products primarily for the respiratory and related markets.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . Disclosure: BioSante (BPAX) is a paid online advertising company on Investorideas.com (six thousand five hundred for three months)
www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
Point Roberts, WA - December 15, 2011 - Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for some of the top trading stocks in the sector for Wednesday, December 14, 2011.
Albany Molecular Research, Inc. (NASDAQ:AMRI) shares gained 0.43 (18.53%) to close at $2.75, rebounding from its recent lows and the stock has surged around 35% over the past 3 weeks.
ViroPharma Incorporated (NASDAQ:VPHM) ended higher by 4.21 (17.85%) to close at $27.80 on very unusual volume and made a new 52-week high of $28.34 after the company reported that U.S. health regulators approved a new and expanded label for its antibiotic Vancocin, which the biotechnology company expects will grant the drug three years of protection from generic versions.
Zalicus, Inc. (NASDAQ:ZLCS) rose 0.10 (9.26%) and closed at $1.18, extending its weekly gains to over 24% on increased volume. Zalicus Inc. (Zalicus), formerly CombinatoRx, is a biopharmaceutical company developing drug candidates with a focus on the treatment of pain and inflammation.
Illumina, Inc. (NASDAQ:ILMN) moved higher by 1.25 (4.82%) to end at $27.21, rebounding from its 52-week low made recently. The stock has a 52-week range of $25.57-$79.40. Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.
Cornerstone Therapeutics, Inc. (NASDAQ:CRTX) climbed 0.52 (10.24%) to finish at $5.60 on high volume. Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, developing and commercializing products primarily for the respiratory and related markets.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . Disclosure: BioSante (BPAX) is a paid online advertising company on Investorideas.com (six thousand five hundred for three months)
www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
Electric Car Stock News Alert; (OTCBB: CCGI); Opportunity and Valuation in the EV Charging Market
POINT ROBERTS, December 15, 2011 - www.InvestorIdeas.com, a leader in cleantech research and news for independent investors, publishes the following CFA commentary on Car Charging Group, Inc. (OTCBB: CCGI). The report, Opportunity and Valuation in the Electric Vehicle Charging Market, was issued by Patrick J. Murphy, Murphy Analytics LLC, a provider of sponsored research coverage on small cap stocks.
Opportunity and Valuation in the Electric Vehicle Charging Market
Car Charging Group, Inc. (OTCBB: CCGI), headquartered in Miami, Florida, is one of the nation's fastest growing providers of Electric Vehicle (EV) charging services. The Company's ultimate mission is to establish a nationwide infrastructure, enabling EV and Plug-in Hybrid Electric Vehicle (PHEV) owners to charge their EVs anytime, anywhere in North America and ultimately Europe and Asia. The CCGI strategy is to be a "first in" strategic partner with businesses, municipalities, shopping malls, parking garages, multi-family residential and commercial properties, and others who are expected to have high numbers of EVs at their locations. Since launching operations in 2009, CCGI has developed contractual relationships with 29 leading partners that own more than 6.4 million parking spots. In addition to working with private enterprise, CCGI also pursues public sector opportunities. As an example, the Pennsylvania Department of Environmental Protection[i] announced 12/14/11 that that CCGI has been awarded a $1 million grant to help develop electric vehicle infrastructure by installing charging stations at 17 Turnpike service plazas.
In an attempt to understand the magnitude of the potential demand load increase, and to prepare for the impact the EV market growth may have on the electric grid, the ISO/RTC Council commissioned a study, "Assessment of Plug-in Electric Vehicle Integration with ISO/RTO Systems," in which it was estimated that 1 million to 2.5 million EV's may be on North American roads by 2015 - 2020. The following graphic illustrates the reports conclusion that the "slow" growth scenario is likely to result in 1 million EV by 2020:
Comprised of 10 North American Independent System Operators (ISOs) and Regional Transmission Organizations (RTOs) http://www.isorto.org/atf/cf/%7B5B4E85C6-7EAC-40A0-8DC3-003829518EBD%7D/IRC_Report_Assessment_of_Plug-in_Electric_Vehicle_Integration_with_ISO-RTO_Systems_03232010.pdf
For the period from 2017 - 2030, the study finds that: "This period is considered as the beginning of the mass-market...New technologies, advanced features, and new charging capabilities likely will be available. Third-generation PEVs are likely to begin appearing on the market. Most importantly, the vehicles will likely have appeal to mainstream automotive customers and become mass market products."
With an estimated 842 vehicles per 1,000 citizens in the U.S. alone and the developing world's per capita vehicle ownership ratios still exponentially below those of the U.S., the potential market opportunity for EV's and the charging of EV's is challenging to quantify but not difficult to characterize as very large.
Based on the recent capital raise by EV charging system operator Better Place, it seems clear that investors such as GE, UBS, HSBC and Morgan Stanley have concluded that the opportunity is indeed significant for the right operator. Announced November 11, 2011, Better Place recently completed a $200 million financing that valued the company at $2.25 billion on a post money / fully diluted basis. Better Place also reported that the Company has raised $750 million since its founding in 2007.
The Better Place solution is a model in which batteries are switched out rather than re-charged in the vehicle. According to its corporate description, Better Place"owns and operates a network of battery switch stations and public/personal charge spots, along with the supply of batteries that power the cars, to provide drivers with instant range extension and the convenience to drive, switch and go across an entire region." Better Place also reported that the financing proceeds would be used to expand operations into Western Europe and that other deployments are in progress in two U.S. states and several other countries.
As a private company, Better Place has no obligation to disclose detailed operational and financial data, so it is challenging to analyze its valuation relative to publicly traded companies such as Car Charging Group (OTCBB: CCGI), which as noted previously, has reported that its partner relationships provide access to 6.4 million parking spots, while CCGI's recent market capitalization was under $65 million.. There are publicly traded companies such as iGo, Inc. (NASDAQ: IGOI) and ZAGG Inc. (NASDAQ: ZAGG) whose operations have some degree of comparability to those of Car Charging Group(OTCBB: CCGI). However, like some of the electronics industry titans with some manner of presence in the sector, Car Charging Group's (OTCBB: CCGI) comparables generally have operations that also include products and markets other than EV charging systems.
Regardless of the valuation methodology, given the level at which Better Place recently was valued by a group of sophisticated investors, it seems clear that the market is concluding that there is an opportunity to thrive in the car charging sector. Companies with strong systems, management teams, relationships and competitive positions may be worth a closer look for investors interested in finding a way to take advantage of what seems to be a rapidly expanding EV charging market.
Car Charging Group, Inc (OTCBB: CCGI)
Patrick Murphy Bio:
Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks. Mr. Murphy has nearly 20 years of capital markets experience providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's. In addition to his work with Murphy Analytics, Mr. Murphy also serves as a consultant to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of the University of Notre Dame (1991), with an undergraduate degree in Economics, and earned a Masters Degree in Finance from St. Louis University in 1997. Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St. Louis.
Patrick Murphy Disclaimer:
Readers are advised that the above article is solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. The views expressed herein are based upon the author's analysis of the issuer's public disclosures, and assumes both their accuracy and completeness. The opinions and statements included herein are based on sources (including the companies discussed and public sources) believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. The author has not independently verified the information contained herein. This information is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. You should review a complete information package on all companies, which should include, but not be limited to, the Company's annual report, quarterly reports, press releases and all regulatory filings. The foregoing discussion contains statements which are based on current expectations, estimates and projections, and differences from such expectations, estimates and projections can be expected. The author, Patrick Murphy, was compensated $550 by InvestorIdeas.com for writing this article. Murphy does not own shares of any of the companies mentioned in this article. Mr. Murphy's research firm, Murphy Analytics, may be engaged for the provision of a research report on the Company in the future.
Comprised of 10 North American Independent System Operators (ISOs) and Regional Transmission Organizations (RTOs)
http://www.isorto.org/atf/cf/%7B5B4E85C6-7EAC-40A0-8DC3-003829518EBD%7D/IRC_Report_Assessment_of_Plug-in_Electric_Vehicle_Integration_with_ISO-RTO_Systems_03232010.pdf
http://www1.eere.energy.gov/vehiclesandfuels/facts/2010_fotw617.html
http://www.betterplace.com/the-company-pressroom-pressreleases-detail/index/id/Better%20Place%20Raises%20$200%20Million%20Series%20C%20Financing
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes .Investorideas.com was compensated two thousand five hundred by a third party for to feature CFA Commentary on CCGI, in email distribution with other Investorideas.com partners and network of online media which are also compensated as part of this overall marketing. Investorideas.com compensated Patrick Murphy 550 for producing the article.
Contact Investorideas.com
800 665 0411
POINT ROBERTS, December 15, 2011 - www.InvestorIdeas.com, a leader in cleantech research and news for independent investors, publishes the following CFA commentary on Car Charging Group, Inc. (OTCBB: CCGI). The report, Opportunity and Valuation in the Electric Vehicle Charging Market, was issued by Patrick J. Murphy, Murphy Analytics LLC, a provider of sponsored research coverage on small cap stocks.
Opportunity and Valuation in the Electric Vehicle Charging Market
Car Charging Group, Inc. (OTCBB: CCGI), headquartered in Miami, Florida, is one of the nation's fastest growing providers of Electric Vehicle (EV) charging services. The Company's ultimate mission is to establish a nationwide infrastructure, enabling EV and Plug-in Hybrid Electric Vehicle (PHEV) owners to charge their EVs anytime, anywhere in North America and ultimately Europe and Asia. The CCGI strategy is to be a "first in" strategic partner with businesses, municipalities, shopping malls, parking garages, multi-family residential and commercial properties, and others who are expected to have high numbers of EVs at their locations. Since launching operations in 2009, CCGI has developed contractual relationships with 29 leading partners that own more than 6.4 million parking spots. In addition to working with private enterprise, CCGI also pursues public sector opportunities. As an example, the Pennsylvania Department of Environmental Protection[i] announced 12/14/11 that that CCGI has been awarded a $1 million grant to help develop electric vehicle infrastructure by installing charging stations at 17 Turnpike service plazas.
In an attempt to understand the magnitude of the potential demand load increase, and to prepare for the impact the EV market growth may have on the electric grid, the ISO/RTC Council commissioned a study, "Assessment of Plug-in Electric Vehicle Integration with ISO/RTO Systems," in which it was estimated that 1 million to 2.5 million EV's may be on North American roads by 2015 - 2020. The following graphic illustrates the reports conclusion that the "slow" growth scenario is likely to result in 1 million EV by 2020:
Comprised of 10 North American Independent System Operators (ISOs) and Regional Transmission Organizations (RTOs) http://www.isorto.org/atf/cf/%7B5B4E85C6-7EAC-40A0-8DC3-003829518EBD%7D/IRC_Report_Assessment_of_Plug-in_Electric_Vehicle_Integration_with_ISO-RTO_Systems_03232010.pdf
For the period from 2017 - 2030, the study finds that: "This period is considered as the beginning of the mass-market...New technologies, advanced features, and new charging capabilities likely will be available. Third-generation PEVs are likely to begin appearing on the market. Most importantly, the vehicles will likely have appeal to mainstream automotive customers and become mass market products."With an estimated 842 vehicles per 1,000 citizens in the U.S. alone and the developing world's per capita vehicle ownership ratios still exponentially below those of the U.S., the potential market opportunity for EV's and the charging of EV's is challenging to quantify but not difficult to characterize as very large.
Based on the recent capital raise by EV charging system operator Better Place, it seems clear that investors such as GE, UBS, HSBC and Morgan Stanley have concluded that the opportunity is indeed significant for the right operator. Announced November 11, 2011, Better Place recently completed a $200 million financing that valued the company at $2.25 billion on a post money / fully diluted basis. Better Place also reported that the Company has raised $750 million since its founding in 2007.
The Better Place solution is a model in which batteries are switched out rather than re-charged in the vehicle. According to its corporate description, Better Place"owns and operates a network of battery switch stations and public/personal charge spots, along with the supply of batteries that power the cars, to provide drivers with instant range extension and the convenience to drive, switch and go across an entire region." Better Place also reported that the financing proceeds would be used to expand operations into Western Europe and that other deployments are in progress in two U.S. states and several other countries.
As a private company, Better Place has no obligation to disclose detailed operational and financial data, so it is challenging to analyze its valuation relative to publicly traded companies such as Car Charging Group (OTCBB: CCGI), which as noted previously, has reported that its partner relationships provide access to 6.4 million parking spots, while CCGI's recent market capitalization was under $65 million.. There are publicly traded companies such as iGo, Inc. (NASDAQ: IGOI) and ZAGG Inc. (NASDAQ: ZAGG) whose operations have some degree of comparability to those of Car Charging Group(OTCBB: CCGI). However, like some of the electronics industry titans with some manner of presence in the sector, Car Charging Group's (OTCBB: CCGI) comparables generally have operations that also include products and markets other than EV charging systems.
Regardless of the valuation methodology, given the level at which Better Place recently was valued by a group of sophisticated investors, it seems clear that the market is concluding that there is an opportunity to thrive in the car charging sector. Companies with strong systems, management teams, relationships and competitive positions may be worth a closer look for investors interested in finding a way to take advantage of what seems to be a rapidly expanding EV charging market.
Car Charging Group, Inc (OTCBB: CCGI)
| Select Stock Trading Data | |
| Recent Stock Price: | $1.70 |
| Shares Outstanding: | 36.4 million |
| Float | 8.3 million |
| Recent Market Cap: | $62 million |
| 52 Week Range: | $0.68 - $6.24 |
| Exchange: | OTCBB |
| Ticker: | CCGI |
| URL: | http://www.carcharging.com |
| Data sourced from Yahoo! Finance; otcbb.com | |
Patrick Murphy Bio:
Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks. Mr. Murphy has nearly 20 years of capital markets experience providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's. In addition to his work with Murphy Analytics, Mr. Murphy also serves as a consultant to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of the University of Notre Dame (1991), with an undergraduate degree in Economics, and earned a Masters Degree in Finance from St. Louis University in 1997. Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St. Louis.
Patrick Murphy Disclaimer:
Readers are advised that the above article is solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. The views expressed herein are based upon the author's analysis of the issuer's public disclosures, and assumes both their accuracy and completeness. The opinions and statements included herein are based on sources (including the companies discussed and public sources) believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. The author has not independently verified the information contained herein. This information is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. You should review a complete information package on all companies, which should include, but not be limited to, the Company's annual report, quarterly reports, press releases and all regulatory filings. The foregoing discussion contains statements which are based on current expectations, estimates and projections, and differences from such expectations, estimates and projections can be expected. The author, Patrick Murphy, was compensated $550 by InvestorIdeas.com for writing this article. Murphy does not own shares of any of the companies mentioned in this article. Mr. Murphy's research firm, Murphy Analytics, may be engaged for the provision of a research report on the Company in the future.
Comprised of 10 North American Independent System Operators (ISOs) and Regional Transmission Organizations (RTOs)
http://www.isorto.org/atf/cf/%7B5B4E85C6-7EAC-40A0-8DC3-003829518EBD%7D/IRC_Report_Assessment_of_Plug-in_Electric_Vehicle_Integration_with_ISO-RTO_Systems_03232010.pdf
http://www1.eere.energy.gov/vehiclesandfuels/facts/2010_fotw617.html
http://www.betterplace.com/the-company-pressroom-pressreleases-detail/index/id/Better%20Place%20Raises%20$200%20Million%20Series%20C%20Financing
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes .Investorideas.com was compensated two thousand five hundred by a third party for to feature CFA Commentary on CCGI, in email distribution with other Investorideas.com partners and network of online media which are also compensated as part of this overall marketing. Investorideas.com compensated Patrick Murphy 550 for producing the article.
Contact Investorideas.com
800 665 0411
Wednesday, December 14, 2011
Tuesday's NASDAQ Winners: SYNO, RVSN, CCMP, GEOY
POINT ROBERTS, December 14, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Tuesday December 13th. Nasdaq dropped 32.99 (1.6 %) to close at 2,579.27.
Synovis Life Technologies, Inc. (NASDAQ:SYNO) was the biggest percentage winner and its shares climbed .35 (50.68%) to close at $27.78 after Baxter International Inc agreed to acquire the company in a deal valued at roughly $325 million, which is expected to expand the medical-products maker's presence in regenerative medicine and biosurgery.
RADVISION LTD. (USA) (NASDAQ:RVSN) continued to move higher and added another 15.44% to $9.72 after rising over 16% in the previous trading session. The stock rallied on a report by the Israeli newspaper Globes that the Israeli video conferencing company is in "advanced talks" to be acquired by Avaya for $200 million.
Cabot Microelectronics Corporation (NASDAQ:CCMP) added by 5.78 (14.37%) to close at $45.99 on very unusual volume of 1.38 million shares, compared to its 30-day average volume of 174K shares after the company intends to pay a special cash dividend of $15 per share, or approximately $345 million in aggregate, to its shareholders during the first quarter of calendar year 2012.
GeoEye Inc. (NASDAQ:GEOY) shares jumped 2.29 (12.05%) to end at $21.30, rebounding from its recent lows. GeoEye, Inc. (GeoEye) is a commercial provider of earth imagery, and a provider of image-processing services and geospatial information services to the United States and foreign government defense and intelligence organizations, domestic federal and foreign civil agencies and commercial customers.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Investors get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
POINT ROBERTS, December 14, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Tuesday December 13th. Nasdaq dropped 32.99 (1.6 %) to close at 2,579.27.
Synovis Life Technologies, Inc. (NASDAQ:SYNO) was the biggest percentage winner and its shares climbed .35 (50.68%) to close at $27.78 after Baxter International Inc agreed to acquire the company in a deal valued at roughly $325 million, which is expected to expand the medical-products maker's presence in regenerative medicine and biosurgery.
RADVISION LTD. (USA) (NASDAQ:RVSN) continued to move higher and added another 15.44% to $9.72 after rising over 16% in the previous trading session. The stock rallied on a report by the Israeli newspaper Globes that the Israeli video conferencing company is in "advanced talks" to be acquired by Avaya for $200 million.
Cabot Microelectronics Corporation (NASDAQ:CCMP) added by 5.78 (14.37%) to close at $45.99 on very unusual volume of 1.38 million shares, compared to its 30-day average volume of 174K shares after the company intends to pay a special cash dividend of $15 per share, or approximately $345 million in aggregate, to its shareholders during the first quarter of calendar year 2012.
GeoEye Inc. (NASDAQ:GEOY) shares jumped 2.29 (12.05%) to end at $21.30, rebounding from its recent lows. GeoEye, Inc. (GeoEye) is a commercial provider of earth imagery, and a provider of image-processing services and geospatial information services to the United States and foreign government defense and intelligence organizations, domestic federal and foreign civil agencies and commercial customers.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Investors get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
Infrastructure/ Construction Stock News: Firemans Contractors (OTCBB:FRCN) Wins Dallas Best and Brightest Award
DALLAS - December 14, 2011 - Fireman's Contractors Inc. (OTCBB: FRCN) (OTCQB:FRCN.OB) a parking lot and pavement maintenance company, is pleased to announce a Holiday Open House today to showcase the Company's expanded corporate headquarters. It will be held at 2406 Gravel Road, Fort Worth, Texas , from 6:00 p.m. to 9:00.
"We are pleased to have this opportunity to invite our investors, existing clients and potential clients to celebrate Firemans Contractors growth. Our facilities have, in the last year, expanded 300 percent. Our existing clients include local businesses, regional businesses and Fortune 500 national and international businesses. We anticipate adding new clients in the coming year. They have received a personal invitation to attend our Open House and observe first hand, who and what makes Firemans Contractors the "Contractors You Can Trust."
"Additionally, we will be showcasing our recent "Best and Brightest" Award from the Dallas / Fort Worth Build Expo Show. We have invited all potential clients, including those we recently met at the Build Expo where we showcased our Parking Lot and Pavement Maintenance expertise. We believe our Open House provides an opportunity for existing and potential clients and shareholders to examine our facilities and meet our staff. This represents an excellent opportunity to evaluate the foundation of our client commitment. Our existing clients are our best reference, not only do we appreciate them, but we encourage complete transparency and communication regarding the quality of our work and the level of our commitment to being the "Contractors You Can Trust."
The event is hosted by Renee and Aaron Gilmore.
About the Fireman's Contractors:
Firemans Contractor's, Inc. (OTCBB: FRCN) is a full service contractor providing professional services for commercial and government clients. Services include Road Improvements, Pavement Maintenance, Seal Coating, Parking Lot Striping, Pavement Marking, Asphalt Maintenance and Repair, and ADA Compliance. Firemans Contractors has completed its FDD requirements with the Federal Trade Commission and has developed franchise territories across the U.S. The Company's goal is to develop hundreds of new franchise locations in the next 24 to 48 months. Firemans Contractors brings a professional value system delivering outstanding results through honorable customer relationships and repeat business. Local firefighters are supported by a portion of profits which are donated to local Firefighter Associations.
Founded by a Firefighter, Firemans Contractors -- Contractors You Can Trust� This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. Additional information respecting the factors that could materially affect the Company and its operations are contained in its annual report on Form 10K and Form 10-Q as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statement.
Contact:
Fireman's Contractors Inc.
2406 Gravel Road
Fort Worth , TX 76118
Phone: 800-475-1479
info@FiremansContractors.com
http://www.Firemans-Contractors.com
Investor Relations Contact:John Pentony, IR Affiliates
Contact: john@iraffiliates.com
Tel: 469.252.3031
Public Relations Contact: Danielle O'Neal
Contact: PR@FiremansContractors.com
Tel: 800-475-1479
Follow FIREMANS CONTRACTORS, Inc. (OTCBB:FRCN) on Twitter.com
http://twitter.com/#!/firemansco
Follow FIREMANS CONTRACTORS, Inc. (OTCBB:FRCN) on Facebook.com
http://www.facebook.com/FiremansContractors
DALLAS - December 14, 2011 - Fireman's Contractors Inc. (OTCBB: FRCN) (OTCQB:FRCN.OB) a parking lot and pavement maintenance company, is pleased to announce a Holiday Open House today to showcase the Company's expanded corporate headquarters. It will be held at 2406 Gravel Road, Fort Worth, Texas , from 6:00 p.m. to 9:00.
"We are pleased to have this opportunity to invite our investors, existing clients and potential clients to celebrate Firemans Contractors growth. Our facilities have, in the last year, expanded 300 percent. Our existing clients include local businesses, regional businesses and Fortune 500 national and international businesses. We anticipate adding new clients in the coming year. They have received a personal invitation to attend our Open House and observe first hand, who and what makes Firemans Contractors the "Contractors You Can Trust."
"Additionally, we will be showcasing our recent "Best and Brightest" Award from the Dallas / Fort Worth Build Expo Show. We have invited all potential clients, including those we recently met at the Build Expo where we showcased our Parking Lot and Pavement Maintenance expertise. We believe our Open House provides an opportunity for existing and potential clients and shareholders to examine our facilities and meet our staff. This represents an excellent opportunity to evaluate the foundation of our client commitment. Our existing clients are our best reference, not only do we appreciate them, but we encourage complete transparency and communication regarding the quality of our work and the level of our commitment to being the "Contractors You Can Trust."
The event is hosted by Renee and Aaron Gilmore.
About the Fireman's Contractors:
Firemans Contractor's, Inc. (OTCBB: FRCN) is a full service contractor providing professional services for commercial and government clients. Services include Road Improvements, Pavement Maintenance, Seal Coating, Parking Lot Striping, Pavement Marking, Asphalt Maintenance and Repair, and ADA Compliance. Firemans Contractors has completed its FDD requirements with the Federal Trade Commission and has developed franchise territories across the U.S. The Company's goal is to develop hundreds of new franchise locations in the next 24 to 48 months. Firemans Contractors brings a professional value system delivering outstanding results through honorable customer relationships and repeat business. Local firefighters are supported by a portion of profits which are donated to local Firefighter Associations.
Founded by a Firefighter, Firemans Contractors -- Contractors You Can Trust� This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. Additional information respecting the factors that could materially affect the Company and its operations are contained in its annual report on Form 10K and Form 10-Q as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statement.
Contact:
Fireman's Contractors Inc.
2406 Gravel Road
Fort Worth , TX 76118
Phone: 800-475-1479
info@FiremansContractors.com
http://www.Firemans-Contractors.com
Investor Relations Contact:John Pentony, IR Affiliates
Contact: john@iraffiliates.com
Tel: 469.252.3031
Public Relations Contact: Danielle O'Neal
Contact: PR@FiremansContractors.com
Tel: 800-475-1479
Follow FIREMANS CONTRACTORS, Inc. (OTCBB:FRCN) on Twitter.com
http://twitter.com/#!/firemansco
Follow FIREMANS CONTRACTORS, Inc. (OTCBB:FRCN) on Facebook.com
http://www.facebook.com/FiremansContractors
Fireman's Contractors Inc. (OTCBB:FRCN), (OTCQB:FRCN.OB) is a featured construction stock on Investorideas.com
Visit the company profile to learn more: http://www.investorideas.com/CO/FRCN/
Disclaimer/ Disclosure: FRCN has compensated Investorideas.com ten thousand for three months of advertising. All info published is sourced from public files or the Company. This is not a solicitation go buy or sell securities.
OTC Biotech Stock News; Aethlon (OTCBB: AEMD) Reports HIV Breakthrough
San Diego, December 14, 2011 - (Investorideas.com Biotech/PharmaNewswire) HIV Medical Technology News Update - Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic filtration devices to address infectious disease and cancer, reports that researchers have discovered that the Aethlon Hemopurifier® is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS).
Aethlon Medical's Hemopurifier® is a first-in-class therapeutic device that selectively targets the clearance of viruses, immunosuppressive proteins, and disease enhancing exosomes from the entire the entire circulatory system.
Nef or "Negative Factor" protein is a highly abundant HIV accessory protein that plays an essential role in AIDS progression, yet has eluded HIV drug discovery efforts. Nef protein is secreted from infected cells in small membrane-bound packages called "exosomes." These exosomes fuse with non-infected cells and cause a variety of effects, including programmed cell death of CD4+ immune cells, the hallmark of AIDS. The Hemopurifier® provides a strategy to address Nef exosomes, which are present in the blood of HIV infected individuals. In an ex vivo validation study conducted by researchers at Morehouse School of Medicine, a small-scale Hemopurifier® reduced the presence of Nef exosomes in cell-culture fluids by greater than 85% in less than 24 hours. The outcome represents the first demonstration that a medical device can selectively target Nef exosomes.
"It is becoming increasingly clear that many viruses, including HIV, exploit the mechanisms of exosome production for their secretion and pathogenesis," stated Michael Powell, Ph.D., Associate Professor and Director of Proteomics, Microbiology, Biochemistry, and Immunology at Morehouse School of Medicine. "Therefore, therapies that target circulating exosomes hold great promise to advance antiviral strategies."
In addition to Nef exosomes, the Hemopurifier® is the subject of multi-cancer studies against tumor-secreted exosomes that facilitate the ability of cancerous tumors to evade the immune response. Tumor-secreted exosomes are implicated in the survival, growth, and metastasis of cancer. Additionally, the Hemopurifier® is being evaluated in human studies as an adjunct therapy to improve outcomes of HCV patients receiving interferon therapy.
"First and foremost, our clinical focus is to demonstrate that our Hemopurifier® improves the benefit of Hepatitis-C virus (HCV) therapies, stated Jim Joyce, CEO and founder of Aethlon Medical. �However, when considering our previous HIV treatment experience, the emerging insight that we can address Nef exosomes provides a further basis for us to pursue clinical opportunities to treat HIV-infected individuals," stated Jim Joyce, CEO and founder of Aethlon Medical.
In a previous proof-of-principle study, an HIV-infected dialysis patient diagnosed with AIDS received Hemopurifier® therapy during his normal dialysis treatment, resulting in the administration of three weekly Hemopurifier® treatments over the period of one month. The study was conducted in the absence of any antiviral drug administration. In addition to demonstrating treatment safety in an immune-compromised AIDS patient, HIV viral load of the patient was reduced from 102,759 iu/ml at the beginning of treatment one to a final value of 7,978 iu/ml at the end of treatment twelve, representing a 92% reduction. Viral load remained 56% below initial testing values when measured 14-days after last Hemopurifier(r) therapy. Additionally, CD4 t-cell to lymphocyte ratios increased from 13.5% to 18.05% during the study. A ratio below 15% represents a clinical definition of AIDS. The study was conducted at the Sigma New Life Hospital in India.
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture tumor-secreted exosomes and to captureNef protein exosomes and the impact that capture may have on disease conditions, the ability to successfully complete the Medanta HCV study and achieve positive results, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contact:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com
Learn more about OTCBB: AEMD
http://www.investorideas.com/CO/AEMD/
Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes. AEMD has paid Investorideas.com four thousand for the email distribution and online distribution of this release through its network including Stock Profiler and Investorideas.com growing network of online financial media.
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
San Diego, December 14, 2011 - (Investorideas.com Biotech/PharmaNewswire) HIV Medical Technology News Update - Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic filtration devices to address infectious disease and cancer, reports that researchers have discovered that the Aethlon Hemopurifier® is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS).
Aethlon Medical's Hemopurifier® is a first-in-class therapeutic device that selectively targets the clearance of viruses, immunosuppressive proteins, and disease enhancing exosomes from the entire the entire circulatory system.
Nef or "Negative Factor" protein is a highly abundant HIV accessory protein that plays an essential role in AIDS progression, yet has eluded HIV drug discovery efforts. Nef protein is secreted from infected cells in small membrane-bound packages called "exosomes." These exosomes fuse with non-infected cells and cause a variety of effects, including programmed cell death of CD4+ immune cells, the hallmark of AIDS. The Hemopurifier® provides a strategy to address Nef exosomes, which are present in the blood of HIV infected individuals. In an ex vivo validation study conducted by researchers at Morehouse School of Medicine, a small-scale Hemopurifier® reduced the presence of Nef exosomes in cell-culture fluids by greater than 85% in less than 24 hours. The outcome represents the first demonstration that a medical device can selectively target Nef exosomes.
"It is becoming increasingly clear that many viruses, including HIV, exploit the mechanisms of exosome production for their secretion and pathogenesis," stated Michael Powell, Ph.D., Associate Professor and Director of Proteomics, Microbiology, Biochemistry, and Immunology at Morehouse School of Medicine. "Therefore, therapies that target circulating exosomes hold great promise to advance antiviral strategies."
In addition to Nef exosomes, the Hemopurifier® is the subject of multi-cancer studies against tumor-secreted exosomes that facilitate the ability of cancerous tumors to evade the immune response. Tumor-secreted exosomes are implicated in the survival, growth, and metastasis of cancer. Additionally, the Hemopurifier® is being evaluated in human studies as an adjunct therapy to improve outcomes of HCV patients receiving interferon therapy.
"First and foremost, our clinical focus is to demonstrate that our Hemopurifier® improves the benefit of Hepatitis-C virus (HCV) therapies, stated Jim Joyce, CEO and founder of Aethlon Medical. �However, when considering our previous HIV treatment experience, the emerging insight that we can address Nef exosomes provides a further basis for us to pursue clinical opportunities to treat HIV-infected individuals," stated Jim Joyce, CEO and founder of Aethlon Medical.
In a previous proof-of-principle study, an HIV-infected dialysis patient diagnosed with AIDS received Hemopurifier® therapy during his normal dialysis treatment, resulting in the administration of three weekly Hemopurifier® treatments over the period of one month. The study was conducted in the absence of any antiviral drug administration. In addition to demonstrating treatment safety in an immune-compromised AIDS patient, HIV viral load of the patient was reduced from 102,759 iu/ml at the beginning of treatment one to a final value of 7,978 iu/ml at the end of treatment twelve, representing a 92% reduction. Viral load remained 56% below initial testing values when measured 14-days after last Hemopurifier(r) therapy. Additionally, CD4 t-cell to lymphocyte ratios increased from 13.5% to 18.05% during the study. A ratio below 15% represents a clinical definition of AIDS. The study was conducted at the Sigma New Life Hospital in India.
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture tumor-secreted exosomes and to captureNef protein exosomes and the impact that capture may have on disease conditions, the ability to successfully complete the Medanta HCV study and achieve positive results, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contact:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com
Learn more about OTCBB: AEMD
http://www.investorideas.com/CO/AEMD/
Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes. AEMD has paid Investorideas.com four thousand for the email distribution and online distribution of this release through its network including Stock Profiler and Investorideas.com growing network of online financial media.
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Tuesday's TSX Trading Leaders: (TSX: CLL), (TSX: LSG), (TSX: MFC), (TSX: IVN)
December 14, 2011 - Investorideas.com, a leader in sector research for independent investors issues a trading alert for TSX trading leaders for December 13, 2011. The Standard & Poor's/TSX Composite Index plunged 147.95 (1.24%) to close the day at 11,759.94.
Connacher Oil and Gas Limited (TSX: CLL) shares were the most actively traded on the TSX and fell 0.12 (13.33%) to close the day at C$0.78 on over 18.68 million shares. The company said that its board has decided not to pursue the unsolicited takeover offer it received from a third party, sending shares down around 10%. The company said the offer was not "compelling", and that it continues to pursue joint venture deals.
Lake Shore Gold Corp. (TSX: LSG) slid 0.08 (6.20%) to C$1.21 on over 3.60 million shares, compared to its average volume of 3.89 million shares as gold prices slid another 2%. Lake Shore Gold Corp. (Lake Shore Gold) is a gold mining company. It is engaged in exploration and development of a number of projects and exploration properties.
Manulife Financial Corp. (TSX: MFC) fell 0.38 (3.48%) to end at C$10.53 with the broader market correction. Manulife Financial Corporation (MFC) is a life insurance and a holding company of The Manufacturers Life Insurance Company (MLI) and John Hancock Reassurance Company, Ltd. MFC is a financial services company serving customers in 22 countries around the world.
Ivanhoe Mines, Ltd.(TSX:IVN) fell 4.71 (22.13%) to close at C$16.67 after Rio Tinto may consider raising its stake in Ivanhoe, but says it doesn't currently plan a takeover bid for the copper and gold miner.
About InvestorIdeas.com: Big Ideas for small cap Investors
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Become a Member
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only 13 stock directories in leading sectors including nanotech, renewable energy, water and energy stocks. Get stock alerts and hot news!
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411
December 14, 2011 - Investorideas.com, a leader in sector research for independent investors issues a trading alert for TSX trading leaders for December 13, 2011. The Standard & Poor's/TSX Composite Index plunged 147.95 (1.24%) to close the day at 11,759.94.
Connacher Oil and Gas Limited (TSX: CLL) shares were the most actively traded on the TSX and fell 0.12 (13.33%) to close the day at C$0.78 on over 18.68 million shares. The company said that its board has decided not to pursue the unsolicited takeover offer it received from a third party, sending shares down around 10%. The company said the offer was not "compelling", and that it continues to pursue joint venture deals.
Lake Shore Gold Corp. (TSX: LSG) slid 0.08 (6.20%) to C$1.21 on over 3.60 million shares, compared to its average volume of 3.89 million shares as gold prices slid another 2%. Lake Shore Gold Corp. (Lake Shore Gold) is a gold mining company. It is engaged in exploration and development of a number of projects and exploration properties.
Manulife Financial Corp. (TSX: MFC) fell 0.38 (3.48%) to end at C$10.53 with the broader market correction. Manulife Financial Corporation (MFC) is a life insurance and a holding company of The Manufacturers Life Insurance Company (MLI) and John Hancock Reassurance Company, Ltd. MFC is a financial services company serving customers in 22 countries around the world.
Ivanhoe Mines, Ltd.(TSX:IVN) fell 4.71 (22.13%) to close at C$16.67 after Rio Tinto may consider raising its stake in Ivanhoe, but says it doesn't currently plan a takeover bid for the copper and gold miner.
About InvestorIdeas.com: Big Ideas for small cap Investors
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Become a Member
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only 13 stock directories in leading sectors including nanotech, renewable energy, water and energy stocks. Get stock alerts and hot news!
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411
Pharma News: Unity Management Group (OTC: UYMG) Reports Initial Sale of PZ UNO Tablet press to Major Pharmaceutical Company for $500,000.
East Hanover, N.J. - December 14, 2011 (Investorideas.com Newswire) - Unity Management Group, Inc. (OTCBB: UYMG) and its subsidiary, Metropolitan Computing Corporation (MCC) are pleased to announce that it has sold its initial PZ Uno Tablet press to a major pharmaceutical company for $500,000. Due to confidentiality agreements the company is not able to disclose the name of the purchaser. The company did specify that the PZ Uno tablet press would be used for a research and development project for clinical trials for a revolutionary new drug.
Unity Management Group Inc. is pleased with the first sale, and reference point for the new press, and projects sales for the PZ UNO Tablet Press for 2012 to be substantial, said Michael Oliver Director, and Vice president, and he also stated that Unity Management is on pace to finalize their 2011 goals in new sales and finalizing pending orders.
About Unity Management Group, Inc.
Unity Management Group, a health resource company, will continue to provide innovative physician practice management services that offer high value and significant return on investment for physicians practices and hospitals through its three subsidiary companies: United Healthcare Solutions Inc., Unity Technologies Inc., and United Business Services Inc.
The first subsidiary, Unity Business Services, is a full service management company offering solutions in practice management, billing, staffing, contracting, licensing, credentialing, and accounting. Unity Business Services also offers assistance in HIPAA compliance, marketing, and unique solutions for practice start-ups and new practices.
Unity Technologies Inc. is a complete software solutions company offering billing, electronic medical records, and electronic health records for physicians' offices and hospitals.
United Healthcare Solutions, a national company based in Nevada , is a healthcare company will be providing medical, vision and dental plans, as well as PPO and HMO networks.
For more information please go to our website which can be found at www.unitymanagementgroup.com www.mcc-online.com
Text stock to: 313131 for our weekly newsletter
Certain information discussed in this press release may constitute forward-looking statements within the Private Securities Litigation Reform Act of 1995 and the federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions at the time made, it can give no assurance that its expectations will be achieved. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to unpredictable and unanticipated risks, trends and uncertainties such as the Company's inability to accurately forecast its operating results; the Company's potential inability to achieve profitability or generate positive cash flow; the availability of financing; and other risks associated with the Company's business. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequen! t events.
Investor Relations Contact
Michael Oliver
SOURCE: Unity Management Group, Inc.
East Hanover, N.J. - December 14, 2011 (Investorideas.com Newswire) - Unity Management Group, Inc. (OTCBB: UYMG) and its subsidiary, Metropolitan Computing Corporation (MCC) are pleased to announce that it has sold its initial PZ Uno Tablet press to a major pharmaceutical company for $500,000. Due to confidentiality agreements the company is not able to disclose the name of the purchaser. The company did specify that the PZ Uno tablet press would be used for a research and development project for clinical trials for a revolutionary new drug.
Unity Management Group Inc. is pleased with the first sale, and reference point for the new press, and projects sales for the PZ UNO Tablet Press for 2012 to be substantial, said Michael Oliver Director, and Vice president, and he also stated that Unity Management is on pace to finalize their 2011 goals in new sales and finalizing pending orders.
About Unity Management Group, Inc.
Unity Management Group, a health resource company, will continue to provide innovative physician practice management services that offer high value and significant return on investment for physicians practices and hospitals through its three subsidiary companies: United Healthcare Solutions Inc., Unity Technologies Inc., and United Business Services Inc.
The first subsidiary, Unity Business Services, is a full service management company offering solutions in practice management, billing, staffing, contracting, licensing, credentialing, and accounting. Unity Business Services also offers assistance in HIPAA compliance, marketing, and unique solutions for practice start-ups and new practices.
Unity Technologies Inc. is a complete software solutions company offering billing, electronic medical records, and electronic health records for physicians' offices and hospitals.
United Healthcare Solutions, a national company based in Nevada , is a healthcare company will be providing medical, vision and dental plans, as well as PPO and HMO networks.
For more information please go to our website which can be found at www.unitymanagementgroup.com www.mcc-online.com
Text stock to: 313131 for our weekly newsletter
Certain information discussed in this press release may constitute forward-looking statements within the Private Securities Litigation Reform Act of 1995 and the federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions at the time made, it can give no assurance that its expectations will be achieved. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to unpredictable and unanticipated risks, trends and uncertainties such as the Company's inability to accurately forecast its operating results; the Company's potential inability to achieve profitability or generate positive cash flow; the availability of financing; and other risks associated with the Company's business. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequen! t events.
Investor Relations Contact
Michael Oliver
SOURCE: Unity Management Group, Inc.
Tuesday, December 13, 2011
Biotech Trading News Alert: Aethlon Medical (OTCBB: AEMD) Trades Up over 9% on News of HIV-AIDS Research Discovery
Point Roberts, WA - December 13, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for Aethlon Medical, Inc. (OTCBB:AEMD) following news of its HIV-AIDS research discovery. The stock is trading up over 9% on 160,000 shares in morning trading.
Aethlon Medical, Inc. (OTCBB:AEMD) the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier® is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS). The Aethlon Hemopurifier® is a first-in-class therapeutic device that selectively targets the clearance of viruses, immunosuppressive proteins, and disease enhancing exosomes from the entire the entire circulatory system.
Full news: http://finance.yahoo.com/news/Aethlon-Medical-Announces-HIV-prnews-3930211403.html?x=0
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Contact:
James A. Joyce
Chairman and CEO
858.459.7800 x301
learn more about OTCBB: AEMD
http://www.investorideas.com/CO/AEMD/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join: http://www.investorideas.com/membership/
Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes. AEMD has paid Investorideas.com four thousand for the email distribution and online distribution of this release through its network including Stock Profiler and Investorideas.com growing network of online financial media.
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Point Roberts, WA - December 13, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for Aethlon Medical, Inc. (OTCBB:AEMD) following news of its HIV-AIDS research discovery. The stock is trading up over 9% on 160,000 shares in morning trading.
Aethlon Medical, Inc. (OTCBB:AEMD) the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier® is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS). The Aethlon Hemopurifier® is a first-in-class therapeutic device that selectively targets the clearance of viruses, immunosuppressive proteins, and disease enhancing exosomes from the entire the entire circulatory system.Full news: http://finance.yahoo.com/news/Aethlon-Medical-Announces-HIV-prnews-3930211403.html?x=0
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Contact:
James A. Joyce
Chairman and CEO
858.459.7800 x301
learn more about OTCBB: AEMD
http://www.investorideas.com/CO/AEMD/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join: http://www.investorideas.com/membership/
Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes. AEMD has paid Investorideas.com four thousand for the email distribution and online distribution of this release through its network including Stock Profiler and Investorideas.com growing network of online financial media.
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Monday's Renewable Energy Stocks Trading; (OTC: CWET), DSTI, SATC, ACFN
Point Roberts, WA - December 13, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, reports on trading for renewable energy stocks for Monday December 12th.
Wind stock, Clean Wind Energy Tower Inc (OTC:CWET) was a notable gainer and bucked the downward trading as the stock ended higher by 15.79% to $0..22 on over 37.6K shares, extending its weekly gains to over 22%. Clean Wind Energy, Inc. a wholly owned subsidiary of Clean Wind Energy Tower, Inc, has designed and is preparing to develop, and construct large "Downdraft Towers" that use benevolent, non-toxic natural elements to generate electricity and clean water economically by integrating and synthesizing numerous proven as well as emerging technologies.
Solar stock, DayStar Technologies Inc. (NASDAQ:DSTI) shares soared 6.67% to $0.32 on very unusual volume of 38K shares. The stock recently made a new 52-week low of $0.13. DayStar Technologies, Inc. has developed a thin film deposition technology for solar photovoltaic (PV) products. The Company utilizes a one-step sputter deposition process.
SatCon Technology Corporation (NASDAQ:SATC) surged 0.04 (1.13%) to close at $0.67, rebounding from its new 52-week low of $0.67 made in the previous trading session. Satcon Technology Corporation (Satcon) is a clean energy technology provider of utility grade power solutions for the renewable energy market, primarily the large-scale commercial and utility-scale solar photovoltaic (PV) markets.
Acorn Energy, Inc.(NASDAQ:ACFN) shares soared 0.05 (0.92%) to $5.48 on high volume of 50.86K shares after the company said that its 84%-owned DSIT subsidiary received a very significant order from an undisclosed Asian customer.
Advanced Battery Technologies, Inc. (PINK: ABAT) soared 16.67% to $0.350 on light volume of over 748K shares. Advanced Battery Technologies, Inc., (ABAT) is a holding company with one direct subsidiary, Cashtech Investment Limited. Cashtech Investment Limited is also a holding company with two subsidiaries: Harbin ZhongQiang Power-Tech Co., Ltd. (Harbin ZQPT).
More Research: get a full list of global publicly traded green stocks
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or www.renewableenergystocks.com
Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas.com is compensated to distribute and publish content on Clean Wind (CWET) through the Investorideas.com site, newswire and syndicated network (one thousand five hundred) and Investorideas.com owns 50,000 144 shares
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information contact:
Source: www.Investorideas.com
Point Roberts, WA - December 13, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, reports on trading for renewable energy stocks for Monday December 12th.
Wind stock, Clean Wind Energy Tower Inc (OTC:CWET) was a notable gainer and bucked the downward trading as the stock ended higher by 15.79% to $0..22 on over 37.6K shares, extending its weekly gains to over 22%. Clean Wind Energy, Inc. a wholly owned subsidiary of Clean Wind Energy Tower, Inc, has designed and is preparing to develop, and construct large "Downdraft Towers" that use benevolent, non-toxic natural elements to generate electricity and clean water economically by integrating and synthesizing numerous proven as well as emerging technologies.
Solar stock, DayStar Technologies Inc. (NASDAQ:DSTI) shares soared 6.67% to $0.32 on very unusual volume of 38K shares. The stock recently made a new 52-week low of $0.13. DayStar Technologies, Inc. has developed a thin film deposition technology for solar photovoltaic (PV) products. The Company utilizes a one-step sputter deposition process.
SatCon Technology Corporation (NASDAQ:SATC) surged 0.04 (1.13%) to close at $0.67, rebounding from its new 52-week low of $0.67 made in the previous trading session. Satcon Technology Corporation (Satcon) is a clean energy technology provider of utility grade power solutions for the renewable energy market, primarily the large-scale commercial and utility-scale solar photovoltaic (PV) markets.
Acorn Energy, Inc.(NASDAQ:ACFN) shares soared 0.05 (0.92%) to $5.48 on high volume of 50.86K shares after the company said that its 84%-owned DSIT subsidiary received a very significant order from an undisclosed Asian customer.
Advanced Battery Technologies, Inc. (PINK: ABAT) soared 16.67% to $0.350 on light volume of over 748K shares. Advanced Battery Technologies, Inc., (ABAT) is a holding company with one direct subsidiary, Cashtech Investment Limited. Cashtech Investment Limited is also a holding company with two subsidiaries: Harbin ZhongQiang Power-Tech Co., Ltd. (Harbin ZQPT).
More Research: get a full list of global publicly traded green stocks
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or www.renewableenergystocks.com
Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas.com is compensated to distribute and publish content on Clean Wind (CWET) through the Investorideas.com site, newswire and syndicated network (one thousand five hundred) and Investorideas.com owns 50,000 144 shares
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information contact:
Source: www.Investorideas.com
Monday's NASDAQ Winners: SUHN, RVSN, BVSN, CMED
POINT ROBERTS, December 13, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Monday December 12th. NASDAQ fell 34.59 (1.31 %) to end at 2,612.26.
Sun Healthcare Group Inc (NASDAQ:SUNH) was the biggest percentage winner and climbed 0.55 (17.52%) to close at $3.69 after Clinton Group, Inc., the investment manager for Clinton Magnolia Master Fund, Ltd. ("Clinton"), one of the largest investors in Sun Healthcare Group, Inc. (NASDAQ: SUNH) ("Sun"), sent a letter to the Board of Directors of Sun to urge the Board to sell the company.
RADVISION LTD. (USA) (NASDAQ:RVSN) shares gained $1.17 (16.14%) to end at $8.42. RADVISION Ltd. is a designer, developer and provider of products and technology that enable real-time voice, video and data communication over packet and mobile 3G (Third Generation) networks, including the Internet and other Internet Protocol, or IP, networks.
BroadVision, Inc. (NASDAQ:BVSN) added by 1.03 (12.56%) to close at $9.23 on very unusual voume of 234K shares, compared to its 30-day average volume of 16K shares. BroadVision Inc. is a provider of electronic commerce ((e-commerce) business solutions. It delivers a combination of technologies and services into the global market. Its offering consists of a framework.
China Medical Technologies, Inc. (NASDAQ:CMED) shares jumped 0.33 (11.11%). Tuesday morning the company announced that the Company intends to implement a debt restructuring plan to improve its balance sheet. The plan may include, without limitation, a debt-for-debt exchange with existing holders of the Company's convertible notes
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
POINT ROBERTS, December 13, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Monday December 12th. NASDAQ fell 34.59 (1.31 %) to end at 2,612.26.
Sun Healthcare Group Inc (NASDAQ:SUNH) was the biggest percentage winner and climbed 0.55 (17.52%) to close at $3.69 after Clinton Group, Inc., the investment manager for Clinton Magnolia Master Fund, Ltd. ("Clinton"), one of the largest investors in Sun Healthcare Group, Inc. (NASDAQ: SUNH) ("Sun"), sent a letter to the Board of Directors of Sun to urge the Board to sell the company.
RADVISION LTD. (USA) (NASDAQ:RVSN) shares gained $1.17 (16.14%) to end at $8.42. RADVISION Ltd. is a designer, developer and provider of products and technology that enable real-time voice, video and data communication over packet and mobile 3G (Third Generation) networks, including the Internet and other Internet Protocol, or IP, networks.
BroadVision, Inc. (NASDAQ:BVSN) added by 1.03 (12.56%) to close at $9.23 on very unusual voume of 234K shares, compared to its 30-day average volume of 16K shares. BroadVision Inc. is a provider of electronic commerce ((e-commerce) business solutions. It delivers a combination of technologies and services into the global market. Its offering consists of a framework.
China Medical Technologies, Inc. (NASDAQ:CMED) shares jumped 0.33 (11.11%). Tuesday morning the company announced that the Company intends to implement a debt restructuring plan to improve its balance sheet. The plan may include, without limitation, a debt-for-debt exchange with existing holders of the Company's convertible notes
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
Biotech Stock Investor News Alert; Aethlon Medical (OTCBB: AEMD) Announces HIV-AIDS Research Discovery
San Diego, December 13, 2011 - (Investorideas.com Newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier® is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS). The Aethlon Hemopurifier® is a first-in-class therapeutic device that selectively targets the clearance of viruses, immunosuppressive proteins, and disease enhancing exosomes from the entire the entire circulatory system.
Nef or "Negative Factor" protein is a highly abundant HIV accessory protein that plays an essential role in AIDS progression, yet has eluded HIV drug discovery efforts. Nef protein is secreted from infected cells in small membrane-bound packages called "exosomes." These exosomes fuse with non-infected cells and cause a variety of effects, including programmed cell death of CD4+ immune cells, the hallmark of AIDS. The Hemopurifier ® provides a strategy to address Nef exosomes, which are present in the blood of HIV infected individuals. In an ex vivo validation study conducted by researchers at Morehouse School of Medicine, a small-scale Hemopurifier® reduced the presence of Nef exosomes in cell-culture fluids by greater than 85% in less than 24 hours. The outcome represents the first demonstration that a medical device can selectively target Nef exosomes.
"It is becoming increasingly clear that many viruses, including HIV, exploit the mechanisms of exosome production for their secretion and pathogenesis," stated Michael Powell, Ph.D., Associate Professor and Director of Proteomics, Microbiology, Biochemistry, and Immunology at Morehouse School of Medicine. "Therefore, therapies that target circulating exosomes hold great promise to advance antiviral strategies."
In addition to Nef exosomes, the Hemopurifier® is the subject of multi-cancer studies against tumor-secreted exosomes that facilitate the ability of cancerous tumors to evade the immune response. Tumor-secreted exosomes are implicated in the survival, growth, and metastasis of cancer. Additionally, the Hemopurifier® is being evaluated in human studies as an adjunct therapy to improve outcomes of HCV patients receiving interferon therapy.
" First and foremost, our clinical focus is to demonstrate that our Hemopurifier® improves the benefit of Hepatitis-C virus (HCV) therapies, stated Jim Joyce, CEO and founder of Aethlon Medical. "However, when considering our previous HIV treatment experience, the emerging insight that we can address Nef exosomes provides a further basis for us to pursue clinical opportunities to treat HIV-infected individuals," stated Jim Joyce, CEO and founder of Aethlon Medical.
In a previous proof-of-principle study, an HIV-infected dialysis patient diagnosed with AIDS received Hemopurifier® therapy during his normal dialysis treatment, resulting in the administration of three weekly Hemopurifier® treatments over the period of one month. The study was conducted in the absence of any antiviral drug administration. In addition to demonstrating treatment safety in an immune-compromised AIDS patient, HIV viral load of the patient was reduced from 102,759 iu/ml at the beginning of treatment one to a final value of 7,978 iu/ml at the end of treatment twelve, representing a 92% reduction. Viral load remained 56% below initial testing values when measured 14-days after last Hemopurifier(r) therapy. Additionally, CD4 t-cell to lymphocyte ratios increased from 13.5% to 18.05% during the study. A ratio below 15% represents a clinical definition of AIDS. The study was conducted at the Sigma New Life Hospital in India.
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture tumor-secreted exosomes and to captureNef protein exosomes and the impact that capture may have on disease conditions, the ability to successfully complete the Medanta HCV study and achieve positive results, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contact:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com
Learn more about OTCBB: AEMD
http://www.investorideas.com/CO/AEMD/
Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes. AEMD has paid Investorideas.com four thousand for the email distribution and online distribution of this release through its network including Stock Profiler and Investorideas.com growing network of online financial media.
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
San Diego, December 13, 2011 - (Investorideas.com Newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier® is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS). The Aethlon Hemopurifier® is a first-in-class therapeutic device that selectively targets the clearance of viruses, immunosuppressive proteins, and disease enhancing exosomes from the entire the entire circulatory system.
Nef or "Negative Factor" protein is a highly abundant HIV accessory protein that plays an essential role in AIDS progression, yet has eluded HIV drug discovery efforts. Nef protein is secreted from infected cells in small membrane-bound packages called "exosomes." These exosomes fuse with non-infected cells and cause a variety of effects, including programmed cell death of CD4+ immune cells, the hallmark of AIDS. The Hemopurifier ® provides a strategy to address Nef exosomes, which are present in the blood of HIV infected individuals. In an ex vivo validation study conducted by researchers at Morehouse School of Medicine, a small-scale Hemopurifier® reduced the presence of Nef exosomes in cell-culture fluids by greater than 85% in less than 24 hours. The outcome represents the first demonstration that a medical device can selectively target Nef exosomes.
"It is becoming increasingly clear that many viruses, including HIV, exploit the mechanisms of exosome production for their secretion and pathogenesis," stated Michael Powell, Ph.D., Associate Professor and Director of Proteomics, Microbiology, Biochemistry, and Immunology at Morehouse School of Medicine. "Therefore, therapies that target circulating exosomes hold great promise to advance antiviral strategies."
In addition to Nef exosomes, the Hemopurifier® is the subject of multi-cancer studies against tumor-secreted exosomes that facilitate the ability of cancerous tumors to evade the immune response. Tumor-secreted exosomes are implicated in the survival, growth, and metastasis of cancer. Additionally, the Hemopurifier® is being evaluated in human studies as an adjunct therapy to improve outcomes of HCV patients receiving interferon therapy.
" First and foremost, our clinical focus is to demonstrate that our Hemopurifier® improves the benefit of Hepatitis-C virus (HCV) therapies, stated Jim Joyce, CEO and founder of Aethlon Medical. "However, when considering our previous HIV treatment experience, the emerging insight that we can address Nef exosomes provides a further basis for us to pursue clinical opportunities to treat HIV-infected individuals," stated Jim Joyce, CEO and founder of Aethlon Medical.
In a previous proof-of-principle study, an HIV-infected dialysis patient diagnosed with AIDS received Hemopurifier® therapy during his normal dialysis treatment, resulting in the administration of three weekly Hemopurifier® treatments over the period of one month. The study was conducted in the absence of any antiviral drug administration. In addition to demonstrating treatment safety in an immune-compromised AIDS patient, HIV viral load of the patient was reduced from 102,759 iu/ml at the beginning of treatment one to a final value of 7,978 iu/ml at the end of treatment twelve, representing a 92% reduction. Viral load remained 56% below initial testing values when measured 14-days after last Hemopurifier(r) therapy. Additionally, CD4 t-cell to lymphocyte ratios increased from 13.5% to 18.05% during the study. A ratio below 15% represents a clinical definition of AIDS. The study was conducted at the Sigma New Life Hospital in India.
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture tumor-secreted exosomes and to captureNef protein exosomes and the impact that capture may have on disease conditions, the ability to successfully complete the Medanta HCV study and achieve positive results, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contact:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com
Learn more about OTCBB: AEMD
http://www.investorideas.com/CO/AEMD/
Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes. AEMD has paid Investorideas.com four thousand for the email distribution and online distribution of this release through its network including Stock Profiler and Investorideas.com growing network of online financial media.
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Subscribe to:
Posts (Atom)